Risk of incident type 2 diabetes with romosozumab versus denosumab in patients with osteoporosis: A global real-world cohort study
Authors:
- Chui-Jia FarnCFChui-Jia Farn
- I-Ching ChiangICI-Ching Chiang
- Hung-Kuan YenHYHung-Kuan Yen
- Mao-Yi YangMYMao-Yi Yang
- I-Hsin ChenICI-Hsin Chen
- I-Weng YenIYI-Weng Yen
- Tzu-Hao TsengTTTzu-Hao Tseng
- Shau-Huai FuSFShau-Huai Fu
- Chen-Yu WangCWChen-Yu Wang
- 5 November 2026
- journal article
- Published by Elsevier in Diabetes & Metabolism
- Vol. 52 (6)
Abstract
No abstract availableThis publication has 26 references indexed in Scilit:
- Antiresorptive Consolidation After Osteoanabolic TherapyJAMA Internal Medicine, 2026
- OsteoporosisThe Lancet, 2025
- LGR4 is essential for maintaining β-cell homeostasis through suppression of RANKMolecular Metabolism, 2025
- Denosumab and the Risk of Diabetes in Patients Treated for OsteoporosisJAMA Network Open, 2024
- One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension StudyJournal of Bone and Mineral Research, 2018
- Effect of denosumab on fasting glucose in women with diabetes or prediabetes from the FREEDOM trialDiabetes/Metabolism Research and Reviews, 2018
- Osteocyte-Secreted Wnt Signaling Inhibitor Sclerostin Contributes to Beige Adipogenesis in Peripheral Fat DepotsJournal of Bone and Mineral Research, 2016
- Osteoprotegerin and Denosumab Stimulate Human Beta Cell Proliferation through Inhibition of the Receptor Activator of NF-κB Ligand PathwayCell Metabolism, 2015
- Outcome of glucose homeostasis in patients with glucocorticoid-induced osteoporosis undergoing treatment with bone active-drugsBone, 2014
- Effects of antiresorptive therapies on glucose metabolism: Results from the FIT, HORIZON-PFT, and FREEDOM trialsJournal of Bone and Mineral Research, 2013